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Abstract We describe the isolation of naturally occurring
human intestinal defensins HD-5 and HD-6 from ileal neoblad-
der urine and ileal mucosa. Using an antibody-based detection
assay, we found multiple N-terminally processed forms of HD-5.
The predominant HD-5 forms in tissue were longer than those in
neobladder urine (amino acid (aa) 23^94 and 29^94 versus aa 36^
94, 56^94 and 63^94) suggesting that Paneth cells store
prodefensin that is processed to mature defensin during or after
degranulation. Search for mature HD-6 yielded aa 69^100 as the
predominant form in both sources. The ileal neobladder is a
promising model to study human Paneth cell secretion.
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1. Introduction
In humans and other mammals, host defense of the small
intestine is attained by both innate and adaptive immune re-
sponses. Of particular interest are the Paneth cells, specialized
epithelial cells implicated in innate host defense. Paneth cells
are located in the intestinal crypts, and originate from the
intestinal stem cells that also generate enterocytes, goblet cells,
and enterochroma⁄n cells (reviewed in [1]). Paneth cells con-
tain numerous secretory granules that are released into the
intestinal lumen upon cholinergic stimulation and bacterial
challenge [2,3]. In mice and rats, lysozyme, group II phospho-
lipase A2 (PLA2) and intestinal defensins (cryptdins) have
been well studied as antimicrobial components of the Paneth
cell granules [2^6]. These antimicrobial polypeptides could
reach high concentrations within the tight con¢nes of the
crypt and could prevent the colonization and invasion of
the stem cells located adjacent to the Paneth cells (reviewed
in [7]). Unfortunately, the extrapolation from animal models
to the human is complicated by the known variability of Pan-
eth cell distribution when diverse mammalian species are com-
pared, with some mammals lacking Paneth cells altogether [8].
The properties of human intestinal mucosa as an antimicro-
bial barrier have been relatively inaccessible to experimental
investigation. Studies of live human Paneth cells have been
limited by the lack of an immortalized Paneth cell line and
the restricted availability of fresh tissue. In particular,
although two human Paneth cell defensin genes have been
cloned [9,10] and their gene structure and developmental ex-
pression characterized [11], the corresponding peptides have
not been isolated. In search of a feasible human model of
Paneth cell function, we studied urine voided through ileal
neobladders [12,13], documented that it contains Paneth cell
associated polypeptides, and for the ¢rst time isolated the
naturally occurring human Paneth cell defensins HD-5 and
HD-6.
2. Materials and methods
2.1. Ileal neobladder urine
We studied patients (UCLA IRB #97-11-026-01A) who were
treated with radical cystoprostatectomy and ileal neobladder recon-
struction for transitional cell carcinoma of the bladder. In all patients,
the tumor was con¢ned to the bladder. The Studer procedure was
used with modi¢cations to fashion a continent ileal reservoir using a
40^60 cm segment of ileum that was at least 10 cm proximal from the
ileocecal valve [12,13]. From 3 days to 2 weeks after surgery, urine
was collected through abdominal drains ¢rst, and later, when possible,
as voided through the urethra.
2.2. Peptide extraction from urine ^ preparative scale
Larger tissue and mucous particles in urine collected from ileal
neobladders were removed by sedimentation and ¢ltration through
100 Wm polypropylene meshes (SpectraPor, Spectrum, Houston,
TX). Cellular particles were removed by centrifugation at 3600Ug
for 10 min and subsequent vacuum-aided ¢ltration through ¢lter pa-
per (No. 4; Whatman, Clifton, NJ). The cleared urine was adjusted to
pH 7.0 with ammonium hydroxide or concentrated glacial acetic acid,
and cationic components were adsorbed with a weak cation exchange
matrix (Macro-Prep CM (carboxymethyl) support, Bio-Rad Labora-
tories, Hercules, CA) added at a 1:500 ratio of matrix to urine vol-
ume. In preliminary experiments we had found that HD-5 binding to
the CM matrix was optimal at pH 6.5^7.5. After overnight incubation
under constant gentle stirring at 4‡C the CM matrix was sedimented
at 1Ug. The supernatant was reextracted as before and batches of
matrix from both extractions were further processed in the same man-
ner but separately. The CM matrix was pelleted at 1000Ug for 5 min
and washed once with 10^100 volumes of 10 mM sodium phosphate
bu¡er, pH 7.0 for 15 min at room temperature under constant agi-
tation followed by centrifugation as above. Thereafter a 50% slurry of
the CM matrix was prepared with 10 mM sodium phosphate bu¡er,
pH 7.0, poured into a column and washed with 10 mM sodium phos-
phate bu¡er, pH 7.0 until a stable absorbance at 280 nm was
achieved. Absorbed cations were eluted with 5% acetic acid. Fractions
containing HD-5 were identi¢ed by Western blot with polyclonal anti-
bodies against recombinant HD-5 [14], lyophilized, pooled in 5% ace-
tic acid and subjected to further puri¢cation as described below.
2.3. Peptide extraction from urine ^ analytical scale
Urine from ileal neobladders was cleared as described in the pre-
vious section. Normal urine and urine from urinary tract infection
(UTI urine; #1: s 105/ml Citrobacter freundii, #2: s 105/ml Proteus
mirabilis ; kindly provided by Dr. David A. Bruckner, Clinical Micro-
biology, UCLA Medical Center) were ¢rst centrifuged at 1500Ug for
10 min and subsequently sterile ¢ltered (0.2 Wm Nalgene, Nalge Nunc
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International, Rochester, NY). If necessary, the urines were adjusted
to pH 7.0 with ammonium hydroxide or concentrated glacial acetic
acid. 20 ml of urine was incubated with 100 Wl of the CM matrix
overnight under constant gentle agitation at 4‡C followed by centri-
fugation at 1500Ug for 5 min. The matrix was washed three times in
10 mM sodium phosphate bu¡er, pH 7.0 for 5 min each at room
temperature under constant gentle agitation and subsequently centri-
fuged for 5 min. Absorbed cations were eluted in two steps. First 200
Wl of 10% acetic acid was added for 1 h, followed by centrifugation as
above. Then 1 ml of 5% acetic acid was added to the matrix overnight
at 4‡C under constant gentle agitation and the supernatant collected
after centrifugation as above was pooled with the 10% acetic acid
eluate. Aliquots of the combined eluate were lyophilized and subjected
to acid urea-PAGE (AU-PAGE) followed by Western blot analysis.
2.4. Dot blot and Western blot
PVDF membrane (Immobilon P or for sequencing Immobilon PSQ,
Millipore, Bedford, MA) was brie£y wetted in methanol and rinsed in
dH2O. For dot blot, peptides were lyophilized, resuspended in 2 Wl
0.01% acetic acid, deposited onto the membrane, and allowed to ad-
sorb for 30 min at 4‡C in a humid chamber. Recombinant proHD-5/
HD-5, phospholipase A2 from human tears (kindly provided by Dr.
Xiao-Dan Qu, UCLA, Department of Medicine) and human breast
milk lysozyme puri¢ed in our laboratory were included as standards.
For Western blot, peptides were electroblotted from AU-PAGE to the
membrane in 0.7% acetic acid/10% methanol at RT with 0.18 A for 10
min omitting prior soaking of the gel in transfer bu¡er to minimize
peptide losses [15]. Longer blotting times caused migration of peptide
bands through the membrane. After ¢xation with 0.05% glutaralde-
hyde in TBS for 1^2 h the blots were blocked for 30 min with 3%
gelatin in TBS and incubated overnight at RT with polyclonal rabbit
serum against either HD-5 (1:2000) or PLA2 (1:5000; a generous gift
from Dr. Timo J. Nevalainen [16]) or human lysozyme (1:100,
DAKO, Carpinteria, CA) diluted in 1% gelatin in TBS containing
0.01% thimerosal as preservative. Thereafter blots were brie£y rinsed
with water, washed three times with TBS containing 0.05% Tween 20,
incubated for 1 h with alkaline phosphatase-conjugated goat anti-
rabbit IgG (Pierce, Rockford, IL) 1:2000 in 1% gelatin in TBS,
washed as before and developed as described previously [14].
2.5. Isolation of human defensin HD-5
Initially, CM-macroprep extracts were directly subjected to reverse-
phase high-pressure liquid chromatography (RP-HPLC) with a 7.8
mmU300 mm Waters C18 column (Delta Pak) eluted by a gradient
of acetonitrile in 0.1% tri£uoroacetic acid (TFA) from 1% to 21%
during the ¢rst 10 min, followed by an increment to 31% during the
following 40 min and an increment to 61% within 15 min. Fractions
eluting between 21% and 41% acetonitrile were analyzed by dot blot
assay for HD-5. The presence of HD-5 was con¢rmed by AU-PAGE
Western blot and fractions containing at least 3 Wg of HD-5 peptide as
estimated by reactivity of recombinant HD-5 and proHD-5 standards
were subjected to a second RP-HPLC on a 3.9 mmU150 mm Waters
C18 column (Delta Pak) with 0.1% hepta£uorobutyric acid (HFBA)
as pairing agent and an acetonitrile gradient from 1% to 35% during
the ¢rst 17 min, followed by an increment to 41% during the following
24 min and an increment to 61%/min during the last 10 min. All peak
fractions were again analyzed as above and HD-5 containing fractions
of at least 80% homogeneity were subjected to sequencing and mass
spectrum analysis. In samples of 6 80% homogeneity, peptides were
electroblotted to Immobilon PSQ membrane, brie£y soaked in amido
black stain (0.4% naphthol blue black, Sigma, 25% isopropanol, 10%
acetic acid), destained with water and bands corresponding to HD-5
reactive bands in a duplicate Western blot were cut out and subjected
to sequencing.
To obtain highly puri¢ed HD-5, CM-macroprep extracts were ¢rst
desalted on a G10 Sephadex column (Pharmacia Biotech, Piscataway,
NJ), then subjected to continuous preparative gel electrophoresis as
described before [14] and fractions containing HD-5 as determined by
Western blot analysis were subjected to RP-HPLC with TFA and ^ if
necessary ^ with HFBA according to the procedure above.
2.6. Isolation of human defensin HD-6
Peptides that eluted from C18 HPLC columns at 25^35% acetoni-
trile in 0.01% TFA (characteristic of most defensins) and had a de-
fensin-like electrophoretic mobility in AU-PAGE but were not lyso-
zyme or the defensins HD-5, HNP1^3, HBD-1 as determined by dot
blot analysis, were subjected to N-terminal amino acid sequencing and
mass spectrum analysis. For further puri¢cation, RP-HPLC fractions
eluting between 24 and 29% acetonitrile in 0.1% TFA and containing
a peptide comigrating with lysozyme (elution at V39% acetonitrile in
0.01% TFA) in AU-PAGE were subjected to a second RP-HPLC
using HFBA as pairing agent and an acetonitrile increment as de-
scribed above. Peak fractions were analyzed by AU-PAGE and frac-
tions containing a peptide with lysozyme-like mobility were subjected
SDS-Tricine PAGE. If homogeneity was s 80%, N-terminal sequenc-
ing and mass spectrum analysis were performed. Fractions of lower
purity were subjected to AU-PAGE, electroblotted to Immobilon
PSQ membrane, stained with amido black as above and bands comi-
grating with lysozyme standard were cut out and subjected to N-
terminal amino acid sequencing. When continuous gel electrophoresis
was employed, fractions comigrating with lysozyme in AU-PAGE
were reserved for further puri¢cation of HD-6.
2.7. Puri¢cation of HD-5 and HD-6 from human intestinal tissue
Ileal mucosal fragments of approximately 0.5^2 g from four di¡er-
ent donors (kindly provided by D. Scott Strong, Department of Col-
orectal Surgery, CCF, IRB # 1155) were ground under liquid nitrogen
using a mortar and pestle, 5^10 ml of 5% acetic acid was added, the
suspension was sonicated on ice and extracted at 4‡C for 24 h under
constant agitation. Insoluble particles were removed by centrifugation
at 1500Ug for 10 min. The supernatant was diluted 1:10 with water,
supplemented with 5 mM EDTA and 2 mM PMSF and the pH was
increased to 7.0 with ammonium hydroxide followed by a second
centrifugation to remove newly formed precipitates. Then CM matrix
was added at a ratio of matrix to tissue extract of 1:50 and cationic
peptides were allowed to bind to the matrix overnight at 4‡C under
constant gentle agitation. After centrifugation at 1500Ug for 5 min
the matrix was washed three times with 10 mM sodium phosphate
bu¡er, pH 7.0, and peptides were eluted with acetic acid as described
for the analytical urine extractions, ¢rst with twice the CM matrix
volume of 10% acetic acid and then ¢ve times the CM matrix volume
of 5% acetic acid. Pooled eluates were analyzed by AU-PAGE and
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Table 1
Biochemical characterization of puri¢ed human intestinal defensin forms
Defensin (encoded aa) Peptide form Source % ACN elution
(C18 RP-HPLC)
N-terminal sequence Mass
TFA HFBA Expected MALDI-TOF
HD-5 (1^94) 20^94 r 29^31 37^39 ESLQER 8103 8106
23^94 IL 31.5 37.25 QERADEA 7774 7780
29^94 IL 31.5 37.25 ATTQKQS 7045 7052
36^94 NB 30 38 GEDNQDL 6296 6293
56^94 NB 26 35 TSGSQA 4271 4270
63^94 NB 26.5 35 ATCYCR 3582 3586
64^94 r 24^25 33^35 TCYCR 3511 3510
HD-6 (1^100) 69^100 IL, NB 25 ND AFTCHCRR 3708 3711
Shown are the predominant naturally occurring forms in ileal neobladder urine (NB) and ileum tissue extract (IL) and, for comparison, the
recombinant forms (r). Amino acid sequences are in standard single letter code, and the expected masses are based on all cysteines forming disul¢de
bonds. The accuracy of MALDI-TOF is approximately 0.1% of the measured mass. ND = not determined.
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subsequent Western blot and selected samples further puri¢ed as de-
scribed above by RP-HPLC.
2.8. Peptide identi¢cation
For defensins, N-terminal amino acid sequencing was performed by
the UCLA Protein Microsequencing Facility, mass spectrum analysis
was performed in the UCLA Center for Molecular and Medical Mass
Spectrometry by laser desorption Voyager RP Instrument (PerSeptive
Biosystems, Framingham, MA) and electrospray measurements were
recorded on Sciex API III (Perkin-Elmer, Foster City, CA). Lysozyme
and PLA2 were identi¢ed by Western blot.
2.9. Western blot analysis of human plasma
Blood anticoagulated with 5 mM EDTA was centrifuged at
2000Ug for 10 min at RT and plasma was acidi¢ed to ¢nal 5% acetic
acid to ensure dissociation of any smaller protein bound to a macro-
molecular carrier proteins [17,18], transferred to a 30 kDa molecular
weight cut o¡ centrifugal concentrator (Omega Macrosep, Pall-Fil-
tron, Northborough, MA), and centrifuged at 5000Ug at 4‡C to
separate macromolecules from the peptides of interest. Filtrate was
collected, the retentate diluted ¢ve-fold in 5% acetic acid followed by
repeat centrifugation as above to ensure complete pH-dependent dis-
sociation of small peptides. Resulting ¢ltrates were pooled, transferred
to a 3 kDa molecular weight cut o¡ centrifugal concentrator (Omega
Macrosep, Pall-Filtron, Northborough, MA) and centrifuged at
5000Ug. Dialysis and concentration of the sample was achieved by
repeated addition of 5% acetic acid followed by centrifugation as
above with a ¢nal 300-fold reduction of eluates smaller than 3 kDa.
The sample was lyophilized and subjected to AU-PAGE followed by
Western blot analysis as described above using polyclonal antibodies
against HD-5.
3. Results and discussion
3.1. HD-5 and HD-6 appear as multiple N-terminally processed
forms
Using a polyclonal antibody we detected multiple HD-5
forms in the ileal neobladder urine of each patient. The
most abundant forms were identical in multiple donors (Fig.
1A and Table 1). The shortest form identi¢ed di¡ered from
the engineered version (rHD-5) by only one additional N-ter-
minal amino acid. We next compared the secreted forms
found in ileal neobladder urine with the forms present in ileal
tissue. Numerous tissue forms were detected, overall longer
than those found in urine, indicating that human intestinal
defensin 5 is stored as a precursor in the Paneth cell granules
and then further processed during or after secretion. This is in
contrast to the other granule-associated defensins in humans,
human neutrophil defensins 1^4, that are stored as terminally
processed mature forms [19].
In general, the activity of antimicrobial peptides correlates
with their net cationic charge [20^22] and defensin proforms
consisting of a negatively charged propiece attached to the
cationic mature peptide are much less active than the mature
peptides. Thus, the inactive recombinant prodefensins
proHNP-1 and proHD-5 both exhibit a net charge of +1.
When these propeptides are chemically cleaved, the resulting
mature forms HNP-1 (net charge +3) and rHD-5 (net charge
of +4) exhibit broad spectrum antimicrobial activity [23,24].
The major HD5 forms isolated from the ileal neobladder
urine have net charges between +3 and +5 and are all likely
to be antimicrobial. Detailed antimicrobial testing of each
form will be the focus of future studies.
For other antimicrobial peptides that are stored as inactive
precursors, the inactive propeptide and activating enzymes are
produced by the same cell [25,26]. Proteases found in Paneth
cells include trypsin [27] that cleaves after basic amino acid
residues and matrilysin which has isoleucine and leucine cleav-
age sites [28^30]. Two of the major HD-5 forms found in
neobladder urine start C-terminal to an arginine consistent
with a trypsin cleavage site. The possibility that trypsin is a
key enzyme involved in defensin processing is indirectly sup-
ported by presence of trypsin inhibitors in the Paneth cell
granules [31,32] that could prevent the premature activation
of Paneth cell trypsin. Aminopeptidases from urine [33] or the
intestinal brush border [34,35] could further process HD-5
and generate some of the forms found in the ileal neobladder.
Conversely, the appearance of uncleaved human intestinal de-
fensin aa 36^94 in the ileal neobladder urine could indicate
incomplete processing due to rapid dilution and washout or
unfavorable composition of the neobladder £uid.
We also isolated one major form of the other known intes-
tinal defensin, HD-6, in various ileal neobladder urines and in
both intestinal tissue samples that were fractionated (Fig. 1
and Table 1). Like two of the major forms of HD-5, the major
form of HD-6 is generated by cleavage C-terminal to an argi-
nine residue. Multiple, less abundant, N-terminally processed
forms of HD-6 were also identi¢ed, suggesting that HD-5 and
HD-6 may be processed by the same enzymes. For HD-6, the
strategy for isolation was based on chromatographic proper-
ties, and the spectrum of HD-6 forms isolated cannot be
compared to HD-5 forms, since the latter was detected using
a polyclonal antibody that recognizes both pro- and mature
defensin forms.
We did not ¢nd any defensin peptides that deviated from
the sequences of HD-5 and HD-6 as predicted from their
cDNAs and genes, consistent with our previous study that
con¢rmed the absence of additional defensin genes in human
small intestine [11]. The limited diversity of human intestinal
defensin genes contrasts with the seventeen known murine
intestinal defensin (cryptdin) sequences encoded by a corre-
spondingly large number of genes [36,37]. In humans, diver-
sity of intestinal defensin forms might be generated by di¡er-
ential posttranslational processing, a situation also seen with
the processing of the human urinary L-defensin HBD-1 [18].
3.2. Human intestinal defensin HD-5 and phospholipase A2 in
ileal neobladder urine are Paneth cell associated
In the mucosa of the small intestine, HD-5 is detectable
only in Paneth cells [9,14]. Because of recent ¢ndings that
HD-5 is also expressed in other epithelial cell types in di¡erent
tissues [38,39] we explored the possibility that this defensin
could be produced in the normal or infected urinary tract.
We performed Western blots for HD-5 and two other fre-
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Fig. 1. Amino acid (aa) sequences (single letter code) of cDNA-en-
coded human intestinal prodefensins HD-5 and HD-6 and the N-
termini of puri¢ed peptides. Symbols: predominant natural forms
S,P ; less abundant natural forms 8,W ; ¢lled: from ileal neoblad-
der urine; open: from ileal mucosa extract. The N-terminus of ma-
ture recombinant HD-5 is underlined (residue 64).
E.M. Porter et al./FEBS Letters 434 (1998) 272^276274
quently used Paneth cell markers, PLA2 [16] and lysozyme, on
normal urine and urine from patients with urinary tract in-
fection (Fig. 2A), and also compared ileal neobladder urine to
urine obtained from same patients before they underwent sur-
gery (data not shown). We detected HD-5 and PLA2 consis-
tently at s 10^100 ng/ml in urine obtained from ileal neo-
bladders. In all other urines HD-5 and PLA2 were absent
or inconsistently present at the lowest detection limit (6 2.5
ng/ml, in agreement with PLA2 concentrations described pre-
viously [40] for normal urine). Because we studied most pa-
tients in the immediate postoperative period where the newly
constructed neobladder is subject to bleeding, admixture of
HD5 and PLA2 from blood was possible. However, reported
PLA2 serum levels range from 3.7 to 10.8 ng/ml [41,42] which
is approximately 10-fold lower than the levels we observed in
the ileal neobladder urine and we were not able to detect HD-
5 in plasma. Hence, HD-5 and PLA2 in the ileal neobladder
urine originate principally from the ileal mucosa of the neo-
bladder and re£ect Paneth cell secretion, as these cells are the
only source of both HD-5 and PLA2 in the ileum [9,14,16]. In
contrast, lysozyme was not restricted to urine from ileal neo-
bladders but was also readily found in normal urine (V10 ng/
ml) and at increased levels in urine from urinary tract infec-
tion (s 50 ng/ml) and cannot be used as Paneth cell marker in
the ileal neobladder.
3.3. The ileal neobladder is a promising model to study Paneth
cell secretion
The ileal neobladder o¡ers many advantages over human
tissue extraction as a source of small intestinal secretions,
including repeated non-invasive access to the same source
and diminished contamination with non-secreted cellular ma-
terial. As seen on the Coomassie-stained AU-PAGE (Fig. 2B),
ileal neobladder urine contains much more protein than nor-
mal and UTI urine including possibly hitherto unknown Pan-
eth cell products, but when compared to extracts of ileal mu-
cosa, the neobladder urine is much less complex. Previously,
ileal conduit urine was successfully used to purify intestinal
mucus glycoprotein [43]. In the ileal neobladder the original
blood and nerve supply is maintained [12,13] and measure-
ments of HD-5 or PLA2 concentrations in neobladder urine
could also be used to study the physiology of Paneth cell
secretion.
The ileal neobladder has been reported to undergo major
epithelial remodeling during the ¢rst year after surgery, pro-
gressing from early changes such as villous atrophy and in-
crease in crypt length to eventual loss of enterocyte di¡eren-
tiation and function, and the development of a £at mucosa
with increased goblet cell and mucus production [44^48].
However, since islands of intestinal mucosa are maintained
for many years [48,49] the neobladder could remain a useful
source of Paneth cell secretions for a long period after sur-
gery.
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